Sage Group News

Isofol Appoints The Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemother

​​ Isofol (, a clinical stage pharmaceutical company based in Gothenburg, Sweden, announces that following an internal review, it has launched a global program to identify one or more strategic partners for commercialization of its Modufolin® chemotherapy asset. The Sage Group (based in Europe, USA and Asia) has been appointed by Isofol to assist the company in this endeavor. The overall objective is to identify a well-established pharma partner who will work with the company to exploit the value of Modufolin® in what is believed to be a multi billion dollar market. Jan-Eric Osterlund, Executive Chairman of Isofol, said “We are delighted to be working with The Sage Grou